Report Detail

Pharma & Healthcare China Biologic Products Holdings Inc (CBPO) - Financial and Strategic SWOT Analysis Review

  • RnM3557178
  • |
  • 25 June, 2019
  • |
  • China
  • |
  • 69 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

China Biologic Products Holdings Inc (CBPO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

China Biologic Product Holdings Inc (China Biologic) is a biopharmaceutical company that focuses on research and development, production, commercialization of plasma based products. Its products are used for prevention and treatment of life-threatening diseases, immune-deficiency related diseases and during medical emergencies. Its plasma products include human immunoglobulin, human albumin, human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, and human coagulation factor VIII. China Biologic’s other product includes placenta polypeptide. It offers products to hospitals and other healthcare facilities in China.

China Biologic Products Holdings Inc Key Recent Developments

May 10,2019 China Biologic reports financial results for the first quarter of 2019
Mar 06,2019 China Biologic reports financial results for the fourth quarter and fiscal year 2018
Jan 07,2019 China Biologic Reiterates Full Year 2018 Financial Forecast
Dec 14,2018 China Biologic announces dismissal of lawsuit filed in Cayman Islands by former chairman

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Table of Contents

    Table of Contents

      List of Tables

        List of Figures

          Section 1 - About the Company

            China Biologic Products Holdings Inc - Key Facts

              China Biologic Products Holdings Inc - Key Employees

                China Biologic Products Holdings Inc - Key Employee Biographies

                  China Biologic Products Holdings Inc - Major Products and Services

                    China Biologic Products Holdings Inc - History

                      China Biologic Products Holdings Inc - Company Statement

                        China Biologic Products Holdings Inc - Locations And Subsidiaries

                          Head Office

                            Other Locations & Subsidiaries

                              Section 2 – Company Analysis

                                Company Overview

                                  China Biologic Products Holdings Inc - Business Description

                                    Business Segment: Biomaterial Products

                                      Overview

                                        Performance

                                          Business Segment: Biopharmaceutical Segment

                                            Overview

                                              Performance

                                                R&D Overview

                                                  China Biologic Products Holdings Inc - Corporate Strategy

                                                    China Biologic Products Holdings Inc - SWOT Analysis

                                                      SWOT Analysis - Overview

                                                        China Biologic Products Holdings Inc - Strengths

                                                          China Biologic Products Holdings Inc - Weaknesses

                                                            China Biologic Products Holdings Inc - Opportunities

                                                              China Biologic Products Holdings Inc - Threats

                                                                China Biologic Products Holdings Inc - Key Competitors

                                                                  Section 3 – Company Financial Ratios

                                                                    Financial Ratios - Capital Market Ratios

                                                                      Financial Ratios - Annual Ratios

                                                                        Performance Chart

                                                                          Financial Performance

                                                                            Financial Ratios - Interim Ratios

                                                                              Financial Ratios - Ratio Charts

                                                                                Section 4 – Company’s Lifesciences Financial Deals and Alliances

                                                                                  China Biologic Products Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

                                                                                    China Biologic Products Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

                                                                                      China Biologic Products Holdings Inc, Recent Deals Summary

                                                                                        Section 5 – Company’s Recent Developments

                                                                                          May 10, 2019: China Biologic reports financial results for the first quarter of 2019

                                                                                            Mar 06, 2019: China Biologic reports financial results for the fourth quarter and fiscal year 2018

                                                                                              Jan 07, 2019: China Biologic Reiterates Full Year 2018 Financial Forecast

                                                                                                Dec 14, 2018: China Biologic announces dismissal of lawsuit filed in Cayman Islands by former chairman

                                                                                                  Nov 01, 2018: China Biologic reports financial results for the third quarter of 2018

                                                                                                    Aug 28, 2018: China Biologic responds to lawsuit filed in Cayman Islands by former Chairman

                                                                                                      Aug 13, 2018: China Biologic names Bing Li as new CEO

                                                                                                        Aug 03, 2018: China Biologic reports financial results for the second quarter of 2018

                                                                                                          May 04, 2018: China Biologic Reports Financial Results For First Quarter Of 2018

                                                                                                            May 04, 2018: China Biologic Announces First Quarter 2018 Financial Results

                                                                                                              Section 6 – Appendix

                                                                                                                Methodology

                                                                                                                  Ratio Definitions

                                                                                                                    About GlobalData

                                                                                                                      Contact Us

                                                                                                                        Disclaimer

                                                                                                                        Summary:
                                                                                                                        Get latest Market Research Reports on China Biologic Products Holdings Inc (CBPO). Industry analysis & Market Report on China Biologic Products Holdings Inc (CBPO) is a syndicated market report, published as China Biologic Products Holdings Inc (CBPO) - Financial and Strategic SWOT Analysis Review. It is complete Research Study and Industry Analysis of China Biologic Products Holdings Inc (CBPO) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                        Last updated on

                                                                                                                        REPORT YOU MIGHT BE INTERESTED

                                                                                                                        Purchase this Report

                                                                                                                        $500.00
                                                                                                                        $1,000.00
                                                                                                                        $1,500.00
                                                                                                                        386.50
                                                                                                                        773.00
                                                                                                                        1,159.50
                                                                                                                        465.50
                                                                                                                        931.00
                                                                                                                        1,396.50
                                                                                                                        76,345.00
                                                                                                                        152,690.00
                                                                                                                        229,035.00
                                                                                                                        42,200.00
                                                                                                                        84,400.00
                                                                                                                        126,600.00
                                                                                                                        Credit card Logo

                                                                                                                        Related Reports


                                                                                                                        Reason to Buy

                                                                                                                        Request for Sample of this report